Wall Street brokerages predict that Zimmer Biomet Holdings Inc (NYSE:ZBH) will report earnings of $2.26 per share for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Zimmer Biomet’s earnings, with estimates ranging from $2.24 to $2.29. Zimmer Biomet posted earnings per share of $2.18 in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.7%. The company is expected to report its next quarterly earnings results on Friday, February 7th.

According to Zacks, analysts expect that Zimmer Biomet will report full year earnings of $7.83 per share for the current fiscal year, with EPS estimates ranging from $7.80 to $7.86. For the next financial year, analysts forecast that the firm will report earnings of $8.30 per share, with EPS estimates ranging from $8.23 to $8.42. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.75 by $0.02. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Zimmer Biomet had a positive return on equity of 13.71% and a negative net margin of 1.14%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.63 earnings per share.

ZBH has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price objective on shares of Zimmer Biomet in a report on Tuesday, November 5th. Raymond James upped their target price on Zimmer Biomet from $150.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. Zacks Investment Research raised Zimmer Biomet from a “sell” rating to a “hold” rating and set a $149.00 price target for the company in a research note on Sunday, November 3rd. Wells Fargo & Co lifted their price target on Zimmer Biomet from $150.00 to $158.00 and gave the company an “outperform” rating in a research report on Monday, September 9th. Finally, Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $147.24.

ZBH stock opened at $143.40 on Wednesday. The firm’s 50-day moving average is $141.17 and its two-hundred day moving average is $131.34. The company has a market capitalization of $29.50 billion, a price-to-earnings ratio of 18.77, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. Zimmer Biomet has a 52 week low of $96.99 and a 52 week high of $147.52. The company has a current ratio of 1.17, a quick ratio of 0.54 and a debt-to-equity ratio of 0.53.

In related news, insider Didier Deltort sold 360 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the transaction, the insider now owns 1,194 shares of the company’s stock, valued at approximately $166,264.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Aure Bruneau sold 15,171 shares of Zimmer Biomet stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $146.78, for a total transaction of $2,226,799.38. Over the last quarter, insiders sold 15,615 shares of company stock valued at $2,288,725. Corporate insiders own 0.72% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. grew its stake in shares of Zimmer Biomet by 1.3% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 117,666 shares of the medical equipment provider’s stock valued at $15,025,000 after buying an additional 1,465 shares in the last quarter. NEXT Financial Group Inc increased its holdings in shares of Zimmer Biomet by 6,955.0% during the 2nd quarter. NEXT Financial Group Inc now owns 1,411 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 1,391 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Zimmer Biomet by 0.7% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 60,839 shares of the medical equipment provider’s stock valued at $7,164,000 after acquiring an additional 429 shares in the last quarter. FDx Advisors Inc. raised its stake in shares of Zimmer Biomet by 21.5% in the 2nd quarter. FDx Advisors Inc. now owns 2,808 shares of the medical equipment provider’s stock valued at $331,000 after acquiring an additional 496 shares in the last quarter. Finally, Hartford Investment Management Co. lifted its holdings in Zimmer Biomet by 0.7% in the 2nd quarter. Hartford Investment Management Co. now owns 28,711 shares of the medical equipment provider’s stock worth $3,380,000 after purchasing an additional 208 shares during the last quarter. 87.38% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: How is a price target determined?

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.